<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Rural Med</journal-id><journal-id journal-id-type="iso-abbrev">J Rural Med</journal-id><journal-id journal-id-type="publisher-id">JRM</journal-id><journal-title-group><journal-title>Journal of Rural Medicine : JRM</journal-title></journal-title-group><issn pub-type="ppub">1880-487X</issn><issn pub-type="epub">1880-4888</issn><publisher><publisher-name>The Japanese Association of Rural Medicine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25650026</article-id><article-id pub-id-type="pmc">4309344</article-id><article-id pub-id-type="publisher-id">2837</article-id><article-id pub-id-type="doi">10.2185/jrm.6.16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Alendronate and Raloxifene Therapy in the Early Period after Hip
Fracture</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ohishi</surname><given-names>Tsuyoshi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ichikawa</surname><given-names>Tetsuya</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ito</surname><given-names>Takanori</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Koyama</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Miyagi</surname><given-names>Michihito</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hoshino</surname><given-names>Hironobu</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Masaaki</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><aff id="aff1"><label>1</label> Department of Orthopaedic Surgery, Enshu Hospital,
Japan</aff><aff id="aff2"><label>2</label> Department of Orthopaedic Surgery, Narita Memorial Hospital,
Japan</aff><aff id="aff3"><label>3</label> Department of Orthopaedic Surgery, Hamamatsu University
School of Medicine, Japan</aff></contrib-group><author-notes><corresp><label>*</label>Correspondence to: Tsuyoshi Ohishi, Department of
Orthopaedic Surgery, Enshu Hospital, 1-1-1 Chuo, Naka-ku, Hamamatsu, Shizuoka 430-0929,
Japan. e-mail: <email xlink:href="t-ohishi@ken.ja-shizuoka.or.jp">t-ohishi@ken.ja-shizuoka.or.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>7</month><year>2011</year></pub-date><pub-date pub-type="ppub"><year>2011</year></pub-date><volume>6</volume><issue>1</issue><fpage>16</fpage><lpage>21</lpage><permissions><copyright-statement>&#x000a9;2011 The Japanese Association of Rural Medicine</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p><bold>Objective:</bold> The purpose of the present study was to clarify the efficacy of
alendronate and raloxifene for preventing bone loss in patients with hip fracture by
monitoring bone mineral densities (BMDs) and biochemical markers during the 9-month period
after fracture.</p><p><bold>Patients and Methods:</bold> Eighty-two female hip fracture patients from 50 to 99
years old (mean &#x000b1; SD: 81.6 &#x000b1; 9.5) were randomly divided into two groups; there were 46
patients in the alendronate-treated group (group ALN) and 36 patients in the
raloxifene-treated group (group RLX). Drugs were administered to patients six weeks after
their operations. Lumbar spine BMD and neck, trochanter, Ward&#x02019;s and total BMDs of the
contralateral proximal femur, serum intact osteocalcin (intact OC), bone-specific alkaline
phosphatase (BAP) and urinary N-terminal telopeptide of type I collagen (NTX) were
measured just before the start of drug administration and at 9 months thereafter.</p><p><bold>Results:</bold> Twenty-two out of 46 patients in group ALN and 23 out of 36
patients in group RLX completed the study. The most common reason for dropping out was the
patient&#x02019;s failure to visit the outpatient clinic. Trochanter BMD in group ALN tended to
increase by 8.4% compared with the baseline, and total hip BMD in group RLX showed a
significant increase (5.7%), although neck BMD in both groups decreased during the 9
months of treatment (&#x02212;8.7% for group ALN and &#x02212;4.2% for group RLX compared with the
baseline). Spine BMD did not change significantly in eithr group. Serum BAP and urinary
NTX decreased significantly in both groups. Serum intact OC did not change
significantly.</p><p><bold>Conclusions:</bold> Both alendronate and raloxifene have a favorable effect on
trochanter and total BMDs of the contralateral proximal femur in the short period after
hip fracture. However, both drugs could not prevent bone loss in the femoral neck during
the 9 months of treatment.</p></abstract><kwd-group><kwd>alendronate</kwd><kwd>bone mineral density</kwd><kwd>dropout</kwd><kwd>hip fracture</kwd><kwd>raloxifene</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Bone loss following hip fracture is severe even if patients can walk in the early period
after their operations. As a result, it is not uncommon for patients who suffer a hip
fracture to experience a second hip fracture. Indeed, the risk of suffering a second hip
fracture is sixfold greater than the risk of initial hip fracture<sup><sup><xref rid="r1" ref-type="bibr">1</xref></sup>)</sup>. Among patients with bilateral hip
fractures, thirty-eight percent of second hip fractures occur less than 1 year after the
initial fracture<sup><sup><xref rid="r2" ref-type="bibr">2</xref></sup>)</sup>. Prevention
of excess bone loss within one year after hip fracture is therefore essential to prevent
subsequent occurrence of fragility fractures. Alendronate and raloxifene are both first-line
drugs recommended in the guidelines for osteoporosis treatment<sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup>)</sup>. Alendronate reduced the risk of new
vertebral and non-vertebral fractures including hip fractures<sup><sup><xref rid="r4" ref-type="bibr">4</xref></sup><sup>,</sup><sup><xref rid="r5" ref-type="bibr">5</xref></sup><sup>,</sup><sup><xref rid="r6" ref-type="bibr">6</xref></sup>)</sup>.
Raloxifene decreased new vertebral fracture risk and also nonvertebral fracture risk in a
subgroup of women with severe vertebral fractures at baseline<sup><sup><xref rid="r7" ref-type="bibr">7</xref></sup><sup>,</sup><sup><xref rid="r8" ref-type="bibr">8</xref></sup><sup>,</sup><sup><xref rid="r9" ref-type="bibr">9</xref></sup>)</sup>.
Therefore, both alendronate and raloxifene may be expected to prevent bone loss after hip
fracture and prevent subsequent fragility fractures. According to the guidelines for
osteoporosis treatment, patients with a hip fracture are candidates for treatment with
anti-osteoporosis drugs<sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup>)</sup>. In
recent years, the number of hip fracture patients receiving treatment with anti-osteoporosis
drugs has been increasing<sup><sup><xref rid="r10" ref-type="bibr">10</xref></sup><sup>,</sup><sup><xref rid="r11" ref-type="bibr">11</xref></sup>)</sup>.
However, many patients are still not receiving this treatment<sup><sup><xref rid="r12" ref-type="bibr">12</xref></sup><sup>,</sup><sup><xref rid="r13" ref-type="bibr">13</xref></sup><sup>,</sup><sup><xref rid="r14" ref-type="bibr">14</xref></sup><sup>,</sup><sup><xref rid="r15" ref-type="bibr">15</xref></sup>)</sup>.
In the present study, we administered alendronate or raloxifene for 9 months to patients
with hip fractures in the early period after operation and monitored bone mineral densities
(BMDs) and biochemical markers. The primary goal of this study was to investigate the effect
of alendronate or raloxifene on BMD and biochemical markers. The secondary goal was to
investigate the reasons for dropping out during the study.</p></sec><sec sec-type="methods" id="s2"><title>Patients and Methods</title><p>Eighty-two female patients with hip fractures from 50 to 99 years old (mean &#x000b1; SD: 81.6 &#x000b1;
9.5) were recruited at Enshu Hospital (Hamamatsu, Shizuoka, Japan) between 2005 and 2007.
All subjects suffered from hip fractures resulting from a simple fall from standing height
or lower and were admitted to our hospital within 24 hours after incidence of the fracture.
Within 3 days after admission, cementless hemiarthroplasty (Kyocera PerFix) or
osteosynthesis with three 6.5-mm cannulated cancellous screws (Ace Medical) was used to
treated femoral neck fractures, and osteosynthesis with compression hip screws (Ace Medical)
or <italic>&#x003b3;</italic>-nails (Howmedica) was used to treated trochanteric fractures. All
subjects were allowed to walk 3 days after surgery. Patients were excluded if they met any
of the following criteria in the two years before the fracture: 1) were admitted with a
pathologic fracture, 2) had sustained a previous fracture, 3) had a thyroid disorder, 4) had
suffered from alcohol abuse, 5) had taken calcium, vitamin D, bisphosphonate, vitamin K,
thiazide or glucocorticoids supplements, 6) had suffered from osteomalacia after
gastrectomy, 7) had undergone an orchidectomy, 8) were receiving hormone replacement therapy
for prostate disease, 9) were unable to walk or 10) had pseudoarthrosis of the fracture site
and osteonecrosis of the femoral head. Informed consent was obtained from each patient prior
to participation in the study. The patients were randomly divided into two groups. Group ALN
consisted of 46 patients treated orally with 5 mg daily doses of alendronate on an empty
stomach. Group RLX consisted of 36 patients treated orally with 60 mg daily doses of
raloxifene after breakfast. Drugs were administered for 9 months beginning 6 weeks after the
operation. Blood and spot urine samples were obtained at 9:00 to 11:00 AM before drug
administration and 9 months after administration. Bone mineral densities were measured
before administration and 9 months after administration using dual-energy X-ray
absorptiometry (DXA) from a QDR Discovery scanner (Hologic, Inc. Madison, Bedford, MA,
U.S.A.). Bone mineral density in grams per square centimeter was determined for the lumbar
spine (L2-4 in anteroposterior projection) and four regions (femoral neck, trochanter,
Ward&#x02019;s triangle and total hip) in the proximal femur of the contralateral side. The
precision of the integral calcium hydroxyapatite standard was less than 1.0% over time.
Serum levels of intact osteocalcin (intact OC), bone specific alkaline phosphatase (BAP) and
urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) were
measured. Serum intact OC was measured by sandwich enzyme-linked immunosorbent assay using a
commercially available kit (Intact Osteocalcin, Biomedical Technologies Inc., Stoughton, MA,
USA) with intra- and interassay variations of 7% and 10.5%, respectively. Serum BAP was
measured by enzyme-linked immunosorbent assay with intra- and interassay variations of
3.9&#x02013;5.9% and 4.4&#x02013;7.7%, respectively<sup><sup><xref rid="r16" ref-type="bibr">16</xref></sup>)</sup>. The urinary levels of NTX were measured with an enzyme-linked
immunosorbent assay with an intra-assay coefficient of variation was 7%<sup><sup><xref rid="r17" ref-type="bibr">17</xref></sup>)</sup>. The NTx concentration was normalized
to urinary creatinine.</p></sec><sec id="s3"><title>Statistical Analysis</title><p>Data were analyzed using a StatView 5.0 (SAS Institute, Cary, NC, USA) program on a
Macintosh computer. A non-parametric test, followed by a Mann-Whitney U test was used for
comparison of the data between groups. Comparison of two related values within groups was
analyzed by a Wilcoxon signed-rank test. All values except those of biochemical parameters
were expressed as means &#x000b1; standard deviation (SD). Values of biochemical parameters were
expressed as means &#x000b1; standard error (SE). Statistical significance was defined as less than
0.05.</p></sec><sec sec-type="results" id="s4"><title>Results</title><p>Twenty-two out of 46 patients in group ALN and 23 out of 36 patients in group RLX completed
the study. Significant differences were not observed between group ALN and group RLX in
anthropometric, BMDs and biochemical parameters at baseline (<xref rid="tbl_001" ref-type="table">Tables 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1</label><caption><title>Anthropometric data for group ALN and group RLX</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Group ALN</th><th align="center" rowspan="1" colspan="1">Group RLX</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">79.4 &#x000b1; 10.7</td><td align="center" rowspan="1" colspan="1">81.3 &#x000b1; 6.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">146.9 &#x000b1; 7.3</td><td align="center" rowspan="1" colspan="1">146.4 &#x000b1; 6.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">42.8 &#x000b1; 9.8</td><td align="center" rowspan="1" colspan="1">45.7 &#x000b1; 9.1</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">19.7 &#x000b1; 3.4</td><td align="center" rowspan="1" colspan="1">21.2 &#x000b1; 3.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Trochanteric fracture (N) / Neck fracture (N)</td><td align="center" rowspan="1" colspan="1">5/17</td><td align="center" rowspan="1" colspan="1">6/17</td></tr><tr><td align="left" rowspan="1" colspan="1">Osteosynthesis (N)/ Endoprosthesis (N)</td><td align="center" rowspan="1" colspan="1">10/12</td><td align="center" rowspan="1" colspan="1">11/12</td></tr></tbody></table><table-wrap-foot><p>Data are shown as means &#x000b1; SD. BMI: body mass index.</p></table-wrap-foot></table-wrap>,<xref rid="tbl_002" ref-type="table"> 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2</label><caption><title>Changes in bone mineral density in group ALN and group RLX</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">After therapy</th><th align="center" rowspan="1" colspan="1">Percent change</th><th align="center" rowspan="1" colspan="1">P-values</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Lumbar spine BMD (g/cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group ALN</td><td align="center" rowspan="1" colspan="1">0.648 &#x000b1; 0.160</td><td align="center" rowspan="1" colspan="1">0.650 &#x000b1; 0.139</td><td align="center" rowspan="1" colspan="1">1.0 &#x000b1; 6.0%</td><td align="center" rowspan="1" colspan="1">0.476</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group RLX</td><td align="center" rowspan="1" colspan="1">0.737 &#x000b1; 0.171</td><td align="center" rowspan="1" colspan="1">0.701 &#x000b1; 0.195</td><td align="center" rowspan="1" colspan="1">&#x02212;4.7 &#x000b1; 15.5%</td><td align="center" rowspan="1" colspan="1">0.370</td></tr><tr><td align="left" rowspan="1" colspan="1">Neck BMD (g/cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group ALN</td><td align="center" rowspan="1" colspan="1">0.455 &#x000b1; 0.087</td><td align="center" rowspan="1" colspan="1">0.415 &#x000b1; 0.089</td><td align="center" rowspan="1" colspan="1">&#x02212;8.7 &#x000b1; 8.9%</td><td align="center" rowspan="1" colspan="1">0.0008</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group RLX</td><td align="center" rowspan="1" colspan="1">0.465 &#x000b1; 0.138</td><td align="center" rowspan="1" colspan="1">0.430 &#x000b1; 0.107</td><td align="center" rowspan="1" colspan="1">&#x02212;4.2 &#x000b1; 15.4%</td><td align="center" rowspan="1" colspan="1">0.089</td></tr><tr><td align="left" rowspan="1" colspan="1">Trochanter BMD (g/cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group ALN</td><td align="center" rowspan="1" colspan="1">0.352 &#x000b1; 0.096</td><td align="center" rowspan="1" colspan="1">0.382 &#x000b1; 0.095</td><td align="center" rowspan="1" colspan="1">8.4 &#x000b1; 17.2%</td><td align="center" rowspan="1" colspan="1">0.067</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group RLX</td><td align="center" rowspan="1" colspan="1">0.384 &#x000b1; 0.123</td><td align="center" rowspan="1" colspan="1">0.398 &#x000b1; 0.114</td><td align="center" rowspan="1" colspan="1">7.8 &#x000b1; 18.4%</td><td align="center" rowspan="1" colspan="1">0.131</td></tr><tr><td align="left" rowspan="1" colspan="1">Ward&#x02019;s triangle BMD (g/cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group ALN</td><td align="center" rowspan="1" colspan="1">0.261 &#x000b1; 0.089</td><td align="center" rowspan="1" colspan="1">0.266 &#x000b1; 0.081</td><td align="center" rowspan="1" colspan="1">4.2 &#x000b1; 31.7%</td><td align="center" rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group RLX</td><td align="center" rowspan="1" colspan="1">0.297 &#x000b1; 0.157</td><td align="center" rowspan="1" colspan="1">0.275 &#x000b1; 0.129</td><td align="center" rowspan="1" colspan="1">11.1 &#x000b1; 63.2%</td><td align="center" rowspan="1" colspan="1">0.654</td></tr><tr><td align="left" rowspan="1" colspan="1">Total hip BMD (g/cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group ALN</td><td align="center" rowspan="1" colspan="1">0.480 &#x000b1; 0.106</td><td align="center" rowspan="1" colspan="1">0.500 &#x000b1; 0.110</td><td align="center" rowspan="1" colspan="1">3.8 &#x000b1; 11.9%</td><td align="center" rowspan="1" colspan="1">0.131</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group RLX</td><td align="center" rowspan="1" colspan="1">0.508 &#x000b1; 0.143</td><td align="center" rowspan="1" colspan="1">0.527 &#x000b1; 0.146</td><td align="center" rowspan="1" colspan="1">5.7 &#x000b1; 10.8%</td><td align="center" rowspan="1" colspan="1">0.030</td></tr></tbody></table><table-wrap-foot><p>Data are shown as means &#x000b1; SD. BMD: bone mineral density.</p></table-wrap-foot></table-wrap> and<xref rid="tbl_003" ref-type="table"> 3</xref><table-wrap id="tbl_003" orientation="portrait" position="float"><label>Table 3</label><caption><title>Changes in biochemical markers in group ALN and group RLX</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">After therapy</th><th align="center" rowspan="1" colspan="1">Percent change</th><th align="center" rowspan="1" colspan="1">Reference range</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Serum intact OC (ng/ml)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 &#x02013; 7</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group ALN</td><td align="center" rowspan="1" colspan="1">2.78 &#x000b1; 0.45</td><td align="center" rowspan="1" colspan="1">2.02 &#x000b1; 0.32</td><td align="center" rowspan="1" colspan="1">&#x02212;4.3 &#x000b1; 20.0%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group RLX</td><td align="center" rowspan="1" colspan="1">3.24 &#x000b1; 0.55</td><td align="center" rowspan="1" colspan="1">3.04 &#x000b1; 0.61</td><td align="center" rowspan="1" colspan="1">11.8 &#x000b1; 24.2%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Serum BAP (U/L)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">9.6 &#x02013; 35.4</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group ALN</td><td align="center" rowspan="1" colspan="1">38.5 &#x000b1; 2.6</td><td align="center" rowspan="1" colspan="1">27.8 &#x000b1; 2.5**</td><td align="center" rowspan="1" colspan="1">&#x02212;19.2 &#x000b1; 12.4%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group RLX</td><td align="center" rowspan="1" colspan="1">44.5 &#x000b1; 3.2</td><td align="center" rowspan="1" colspan="1">34.4 &#x000b1; 2.6**</td><td align="center" rowspan="1" colspan="1">&#x02212;20.0 &#x000b1; 5.7%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Urinary NTX (nmol BCE/mmol Cr)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14.3 &#x02013; 89.0</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group ALN</td><td align="center" rowspan="1" colspan="1">102.2 &#x000b1; 11.2</td><td align="center" rowspan="1" colspan="1">38.4 &#x000b1; 5.4***</td><td align="center" rowspan="1" colspan="1">&#x02212;55.0 &#x000b1; 8.5%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Group RLX</td><td align="center" rowspan="1" colspan="1">106.8 &#x000b1; 11.7</td><td align="center" rowspan="1" colspan="1">51.2 &#x000b1; 9.4***</td><td align="center" rowspan="1" colspan="1">&#x02212;47.1 &#x000b1; 9.8%</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Values of biochemical markers and percent changes are shown as means &#x000b1; SE. OC:
osteocalcin. BAP: bone-specific alkaline phosphatase. NTX: N-terminal telopeptides of
type I collagen. BCE: bone collagen equivalents of NTX immunoreactivity. ** and ***:
p&#x0003c;0.01 and p&#x0003c;0.001 compared with the baseline values, respectively.</p></table-wrap-foot></table-wrap>). <xref rid="tbl_002" ref-type="table">Table 2</xref> shows values of BMDs at
baseline and 9 months after drug administration. Lumbar spine BMD in both groups did not
change significantly. Although neck BMD decreased significantly, trochanter BMD tended to
increase in group ALN. Ward&#x02019;s BMD did not change significantly in either group. Total BMD in
the proximal femur in group RLX increased significantly. Percent changes in three regions of
the proximal femur compared with the BMD values before drug administration in each group are
also indicated in <xref rid="tbl_002" ref-type="table">Table 2</xref>. In both groups,
trochanter and total BMDs tended to increase; however, neck BMD tended to decrease in spite
of the anti-osteoporosis drug therapy.</p><p>Serum BAP and urinary NTX decreased significantly compared with the baseline values in both
groups (<xref rid="tbl_003" ref-type="table">Table 3</xref>). In particular, urinary NTX in
group ALN decreased by 55.0% compared with the value before drug administration. Serum
intact OC did not change in either group. All patients who completed the study could walk
with a single cane or walking trolley during the study period. For the patients who
completed the study, none of the X-rays showed peseudoarthrosis or osteonecrosis of the
proximal femur or loosening of endoprosthesis at the end of the study.</p><p>As for the dropout rate, 24 patients in group ALN and 13 patients in group RLX failed to
complete the study. The reasons for dropping out in each group are listed in <xref rid="tbl_003" ref-type="table">Table 4</xref><table-wrap id="tbl_004" orientation="portrait" position="float"><label>Table 4</label><caption><title>Reasons for dropping out from the study</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Group ALN (n=24)</th><th align="center" rowspan="1" colspan="1">Group RLX (n=13)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">New contra-lateral hip fracture (n = 1)</td><td align="left" rowspan="1" colspan="1">New contra-lateral hip fracture (n = 1)</td></tr><tr><td align="left" rowspan="1" colspan="1">New vertebral fracture (n = 1)</td><td align="left" rowspan="1" colspan="1">Refracture (n = 1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Device failure (n = 1)</td><td align="left" rowspan="1" colspan="1">Hot flashes (n = 1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Death (n = 1)</td><td align="left" rowspan="1" colspan="1">Heart failure (n = 1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Failure to visit clinic (n = 8)</td><td align="left" rowspan="1" colspan="1">Failure to visit clinic (n = 5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Transfer to other hospital (n = 3)</td><td align="left" rowspan="1" colspan="1">Urine could not be collected (n = 1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Urine could not be collected (n = 2)</td><td align="left" rowspan="1" colspan="1">Others (n = 3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Others (n = 7)</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap>. Two patients in group ALN and one patient in group RLX were withdrawn because
they suffered new fragile fractures during the study. The most common reason for dropping
out was failure to visit the outpatient clinic. Only one patient in group RLX discontinued
drug treatment because of hot flashes, an adverse effect of the drug. One patient
experiencing hot flashes overcame the side effects after cessation of the therapy.</p></sec><sec sec-type="discussion" id="s5"><title>Discussion</title><p>In the present study, neck BMD of the proximal femur in group ALN and in group RLX
decreased significantly, by 8.7% and 4.2% after 9 months of treatment, respectively. Neck
BMD after hip fracture decreased by 4.3&#x02013;9.2% without anti-osteoporosis drug intervention of
the course of one year in previous papers<sup><sup><xref rid="r18" ref-type="bibr">18</xref></sup><sup>,</sup><sup><xref rid="r19" ref-type="bibr">19</xref></sup><sup>,</sup><sup><xref rid="r20" ref-type="bibr">20</xref></sup><sup>,</sup><sup><xref rid="r21" ref-type="bibr">21</xref></sup><sup>,</sup><sup><xref rid="r22" ref-type="bibr">22</xref></sup>)</sup>.
Surprisingly, neck BMD decreased by more compared with the percentage changes in past
studies even when alendronate or raloxifene was administrated. This may partly be due to
neck BMD at the baseline in the present study being lower than that in past studies. In the
present study, the mean values of neck BMD at the baseline in the two groups were 0.455 and
0.465 g/cm<sup>3</sup>; however, those in two past studies were 0.559 and 0.546
g/cm<sup>3</sup>, respectively<sup><sup><xref rid="r19" ref-type="bibr">19</xref></sup><sup>,</sup><sup><xref rid="r20" ref-type="bibr">20</xref></sup>)</sup>.
Trochanter BMD in group ALN tended to increase, and total BMD of the proximal femur in group
RLX increased significantly with the 9 months of anti-osteoporosis drug intervention. Our
results are in good agreement with those reported by Cecilia <italic>et
al</italic>.<sup><sup><xref rid="r23" ref-type="bibr">23</xref></sup>)</sup>. They
investigated antiresorptive efficacy on spine and hip BMDs of alendronate given immediately
after operation in hip fracture patients. Total, trochanteric and intertrochanteric BMDs of
the hip increased significantly after alendronate therapy, while neck BMD did not change
significantly according to their results. In our previous study, vitamin K<sub>2</sub>
prevented bone loss in the Ward&#x02019;s triangle of the contralateral proximal femur after hip
fracture over the course of 9 months<sup><sup><xref rid="r24" ref-type="bibr">24</xref></sup>)</sup>. The anti-osteoporosis effect of alendronate, raloxifene and
vitamin K<sub>2</sub> may first impact cancellous bone rather than cortical bone in the
short term. Trochanter, total and Ward&#x02019;s BMDs reflect cancellous bone predominantly;
however, neck BMD reflects mainly cortical bone. Therefore, the favorable effects of
alendronate and raloxifene were reflected in trochanter and total BMDs rather than neck BMD
in the short period of this study.</p><p>In both groups, serum BAP and urinary NTX decreased significantly during the study period;
however, serum intact OC did not change significantly. Bone resorption markers increased
rapidly after hip fracture, with peak values at 4 to 8 weeks after fracture, and decreased
thereafter up to 12 months, while bone formation markers increased gradually after fracture
up to 12 months<sup><sup><xref rid="r25" ref-type="bibr">25</xref></sup>)</sup>. In this
study, bone resorption marker or NTX decreased significantly compared with the baseline
values during the 9 months because of the strong antiresoptive effect of the drugs. Serum
bone formation marker or BAP decreased during the 9 months because suppression of bone
turnover by the drugs might mask the increased rate of bone formation in the fracture
healing process. The reason for the results of no remarkable changes of serum intact OC
during the study period is that serum intact OC might be less sensitive to both drugs than
serum BAP as an indicator for bone turnover. No previous reports have demonstrated the
changes of intact OC during alendronate or raloxifene therapy after hip fracture. Further
study will be necessary for the use of serum intact OC for monitoring the effect of
drugs.</p><p>Patients with hip fracture are candidates for anti-osteoporosis drug intervention according
to the guidelines for osteoporosis<sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup>)</sup>. Treatment with anti-osteoporosis drugs within 6 months after hip
fracture has improved over the past 10 years, but some authors have reported that
anti-osteoporosis drugs are administered to only 6&#x02013;10% of all hip fracture
patients<sup><sup><xref rid="r26" ref-type="bibr">26</xref></sup><sup>,</sup><sup><xref rid="r27" ref-type="bibr">27</xref></sup>)</sup>. Such a low rate of drug intervention for patients with hip
fracture is not only due to the responsible doctors not prescribing such medicines but also
because of the lower level of patient compliance and persistence with anti-osteoporosis
drugs. In this study, almost half of all the patients who entered the study dropped out. In
particular, more patients in group ALN dropped out than in group RLX. No cases were
withdrawn due to side effect of alendronate. The reason for the group difference in dropout
rate might be that more patients entered the study in group ALN than in group RLX. Some
patients did not visit our outpatient ward every one to three months after discharge as we
directed, although we emphasized the importance of such visits to the patients and their
families for continuing administration of their particular drug to prevent bone loss.
Discontinuance of medicine is the most serious problem hampering prevention of bone loss
after hip fracture. According to Bell <italic>et al</italic>., BMD measurement is not
necessary during the 3 to 5 years after bisphosphonate administration in patients with
osteoporosis since misreadings may occur<sup><sup><xref rid="r28" ref-type="bibr">28</xref></sup>)</sup>. However, we believe the most important thing is keeping the
level of patient compliance with anti-osteoporosis drugs high, since there is evidence that
both alendronate and raloxifene prevent fragile fractures. How can we keep patient
compliance high? In the present study, trochanter or total BMD of the contralateral hip
increased in the short term. If responsible doctors show data for the trochanter or total
hip BMD to their hip fracture patients, patient compliance with anti-osteoporosis drugs may
well improve. In Japan, BMDs for lumbar spine and femoral neck are mostly used to monitor
changes during anti-osteoporosis therapy. We suggest that trochanter and total BMDs of the
proximal femur should also be monitored after hip fracture during anti-osteoporosis drug
therapy.</p><p>One of the limitations of this study is the smaller than expected sample size due to the
surprisingly high dropout rate. Therefore, we focused not only on the effect of alendronate
or raloxifene on BMDs but also the reasons for dropping out. Another limitation is that
control or placebo cases were not available in this study. In our previous study, we
monitored the spine and proximal femur in patients with hip fractures without drug
intervention in the same design as the present study<sup><sup><xref rid="r24" ref-type="bibr">24</xref></sup>)</sup>. That study found that BMDs of the L2-4 spine and 4
regions of the proximal femur decreased during 9 months without anti-osteoporosis drug
intervention after hip fracture.</p><p>In conclusion, both alendronate and raloxifene have a favorable effect on trochanter and
total BMDs of the contralateral proximal femur in the early period after operation for
patients with hip fractures.</p></sec></body><back><ack><p>We wish to give special thanks to Miss Ayako Okamoto for measuring biochemical markers.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Schroder</surname><given-names>HM</given-names></name><name><surname>Petersen</surname><given-names>KK</given-names></name><name><surname>Erlandsen</surname><given-names>M</given-names></name></person-group>
<article-title>Occurrence and incidence of the second hip
fractute</article-title>. <source>Clin Orthop</source><year>1993</year>;
<year>289</year>: <fpage>166</fpage>&#x02013;<lpage>169</lpage>. <pub-id pub-id-type="pmid">8472408</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Boston</surname><given-names>DA</given-names></name></person-group>
<article-title>Bilateral fractures of the femoral neck</article-title>.
<source>Injury</source><year>1983</year>; <year>14</year>:
<fpage>207</fpage>&#x02013;<lpage>210</lpage>. </mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Orimo</surname><given-names>H</given-names></name></person-group> Japanese Guideline for Prevention and Treatment of Osteoporosis. Life
Science <year>2006</year>. </mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Black</surname><given-names>DM</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name><name><surname>Karpf</surname><given-names>DB</given-names></name><etal>et al</etal></person-group><article-title>Randomised trial of effect of alendronate on risk of
fracture in women with existing vertebral fractures</article-title>.
<source>Lancet</source><year>1996</year>; <year>348</year>:
<fpage>1535</fpage>&#x02013;<lpage>1541</lpage>.<pub-id pub-id-type="pmid">8950879</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Cummings</surname><given-names>SR</given-names></name><name><surname>Black</surname><given-names>DM</given-names></name><name><surname>Thompson</surname><given-names>DE</given-names></name><etal>et al</etal></person-group><article-title>Effect of alendronate on risk of fracture in women with
low bone density but without vertebral fractures: results from the fracture intervention
trial</article-title>. <source>JAMA</source><year>1998</year>; <year>280</year>:
<fpage>2077</fpage>&#x02013;<lpage>2082</lpage>.<pub-id pub-id-type="pmid">9875874</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Kushida</surname><given-names>K</given-names></name><name><surname>Shiraki</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Alendronate reduced vertebral fracture risk in
postmenopausal Japanese women with osteoporosis: a 3-year follow-up
study</article-title>. <source>J Bone Miner Metab</source><year>2004</year>;
<year>22</year>: <fpage>462</fpage>&#x02013;<lpage>468</lpage>.<pub-id pub-id-type="pmid">15316867</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Ensrud</surname><given-names>KE</given-names></name><name><surname>Stock</surname><given-names>JL</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Effects of raloxifene on fracture risk in postmenopausal
women: The raloxifene use for the heart trial</article-title>. <source>J Bone Miner
Res</source><year>2008</year>; <year>23</year>:
<fpage>112</fpage>&#x02013;<lpage>120</lpage>.<pub-id pub-id-type="pmid">17892376</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Delmas</surname><given-names>PD</given-names></name><name><surname>Ensrud</surname><given-names>KE</given-names></name><name><surname>Adachi</surname><given-names>JD</given-names></name><etal>et al</etal></person-group><article-title>Efficacy of raloxifene on vertebral fracture risk in
postmenopausal women with osteoporosis: four-year results from a randomized clinical
trial</article-title>. <source>J Clin Endocrinol Metab</source><year>2002</year>;
<year>87</year>: <fpage>3609</fpage>&#x02013;<lpage>3617</lpage>.<pub-id pub-id-type="pmid">12161484</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Delmas</surname><given-names>PD</given-names></name><name><surname>Genant</surname><given-names>HK</given-names></name><name><surname>Crans</surname><given-names>GG</given-names></name><etal>et al</etal></person-group><article-title>Severity of prevalent vertebral fractures and the risk of
subsequent vertebral and nonvertebral fractures: results from the MORE
trial</article-title>. <source>Bone</source><year>2003</year>; <year>33</year>:
<fpage>522</fpage>&#x02013;<lpage>532</lpage>.<pub-id pub-id-type="pmid">14555255</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Gardner</surname><given-names>MJ</given-names></name><name><surname>Flik</surname><given-names>KR</given-names></name><name><surname>Mooar</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Improvement in the undertreatment of osteoporosis
following hip fracture</article-title>. <source>JBJS</source><year>2005</year>;
<volume>84-A</volume>(8): <fpage>1342</fpage>&#x02013;<lpage>1348</lpage>.</mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Cadarette</surname><given-names>SM</given-names></name><name><surname>Katz</surname><given-names>JN</given-names></name><name><surname>Brookhart</surname><given-names>MA</given-names></name><etal>et al</etal></person-group><article-title>Trends in drug prescribing for osteoporosis after hip
fracture, 1995&#x02013;2004</article-title>. <source>J Rheumatol</source><year>2008</year>;
<year>35</year>: <fpage>319</fpage>&#x02013;<lpage>326</lpage>.<pub-id pub-id-type="pmid">18061977</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Feldstein</surname><given-names>AC</given-names></name><name><surname>Nichols</surname><given-names>GA</given-names></name><name><surname>Elmer</surname><given-names>PJ</given-names></name><etal>et al</etal></person-group><article-title>Older women with fractures: patients falling through the
cracks of guideline-recommended osteoporosis screening and treatment</article-title>.
<source>JBJS</source><year>2003</year>; <volume>85-A</volume>(12):
<fpage>2294</fpage>&#x02013;<lpage>2302</lpage>.</mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Hajcsar</surname><given-names>EE</given-names></name><name><surname>Hawker</surname><given-names>G</given-names></name><name><surname>Boboch</surname><given-names>ER</given-names></name></person-group>
<article-title>Investigation and treatment of osteoporosis in patients
with fragility fractures</article-title>. <source>CMAJ</source><year>2000</year>;
<year>163</year>: <fpage>819</fpage>&#x02013;<lpage>822.</lpage><pub-id pub-id-type="pmid">11033708</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Carnevale</surname><given-names>V</given-names></name><name><surname>Nieddu</surname><given-names>L</given-names></name><name><surname>Romagnoli</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Osteoporosis intervention in ambulatory patients with
previous hip fracture: a multicentric, nationwide Italian survey</article-title>.
<source>Osteoporos Int</source><year>2006</year>; <year>17</year>:
<fpage>478</fpage>&#x02013;<lpage>483</lpage>.<pub-id pub-id-type="pmid">16283066</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Liel</surname><given-names>Y</given-names></name><name><surname>Castel</surname><given-names>H</given-names></name><name><surname>Bonneth</surname><given-names>DY</given-names></name></person-group>
<article-title>Impact of subsidizing effective anti-osteoporosis drugs on
compliance with management guidelines in patients following low-impact
fractures</article-title>. <source>Osteoporos Int</source><year>2003</year>;
<year>14</year>: <fpage>490</fpage>&#x02013;<lpage>495</lpage>.<pub-id pub-id-type="pmid">12730761</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Gomez</surname><given-names>B</given-names></name><name><surname>Ardakani</surname><given-names>S</given-names></name><name><surname>Ju</surname><given-names>Julia</given-names></name><name><surname>Jenkins</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Monoclonal antibody assay for measuring bone-specific
alkaline phosphatase activity in serum</article-title>. <source>Clin
Chem</source><year>1995</year>; <year>41</year>:
<fpage>1560</fpage>&#x02013;<lpage>1566</lpage>.<pub-id pub-id-type="pmid">7586543</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Hanson</surname><given-names>DA</given-names></name><name><surname>Weis</surname><given-names>MAE</given-names></name><name><surname>Bollen</surname><given-names>AM</given-names></name><etal>et al</etal></person-group><article-title>A specific immunoassay for monitoring human bone
resorption: quantitation of type I collagen cross-linked N-telopeptides in
urine</article-title>. <source>J Bone Miner Res</source><year>1992</year>;
<year>7</year>: <fpage>1251</fpage>&#x02013;<lpage>1258</lpage>.<pub-id pub-id-type="pmid">1466251</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Dirschl</surname><given-names>DR</given-names></name><name><surname>Henderson</surname><given-names>RC</given-names></name><name><surname>Oakley</surname><given-names>WC</given-names></name></person-group>
<article-title>Accelerated bone mineral loss following a hip fracture: a
prospective longitudinal study</article-title>. <source>Bone</source><year>1997</year>;
<year>20</year>: <fpage>79</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">9213011</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Dirschl</surname><given-names>DR</given-names></name><name><surname>Piedrahita</surname><given-names>L</given-names></name><name><surname>Henderson</surname><given-names>RC</given-names></name></person-group>
<article-title>Bone mineral density 6 years after a hip fracture: A
prospective, longitudinal study</article-title>. <source>Bone</source><year>2000</year>;
<year>26</year>: <fpage>95</fpage>&#x02013;<lpage>98</lpage><pub-id pub-id-type="doi">10.1016/S8756-3282(99)00234-3</pub-id><pub-id pub-id-type="pmid">10617162</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Yu-Yahiro</surname><given-names>J</given-names></name><name><surname>Michael</surname><given-names>RH</given-names></name><name><surname>Dubin</surname><given-names>NH</given-names></name><etal>et al</etal></person-group><article-title>Serum and urine markers of bone metabolism during the year
after hip fracture</article-title>. <source>JAGS</source><year>2001</year>;
<year>49</year>: <fpage>877</fpage>&#x02013;<lpage>883</lpage>.</mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Karachelios</surname><given-names>T</given-names></name><name><surname>Lyritis</surname><given-names>GP</given-names></name><name><surname>Kaloudis</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>The effect of calcitonin on acute bone loss after
peritrochanteric fractures</article-title>. <source>JBJS</source><year>2004</year>;
<year>86-B</year>: <fpage>350</fpage>&#x02013;<lpage>358</lpage>.</mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Hedstrom</surname><given-names>M</given-names></name><name><surname>Sjoberg</surname><given-names>K</given-names></name><name><surname>Svensson</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Changes on biochemical markers of bone metabolism and BMD
during the first year after a hip fracture</article-title>. <source>Acta Orthop
Scand</source><year>2001</year>; <year>72</year>:
<fpage>248</fpage>&#x02013;<lpage>251</lpage>.<pub-id pub-id-type="pmid">11480599</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>Cecilia</surname><given-names>D</given-names></name><name><surname>Jodar</surname><given-names>E</given-names></name><name><surname>Fernandez</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Effect of alendronate in elderly patients after low trauma
hip fracture repair</article-title>. <source>Osteoporos Int</source><year>2009</year>;
<year>20</year>: <fpage>903</fpage>&#x02013;<lpage>910</lpage>.<pub-id pub-id-type="pmid">18956132</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Ohishi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Nagano</surname><given-names>A</given-names></name></person-group>
<article-title>Vitamin K<sub>2</sub> and etidronate therapy in the early
period after hip fracture</article-title>. <source>JRM</source><year>2007</year>;
<year>2</year>: <fpage>105</fpage>&#x02013;<lpage>115</lpage>.</mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Ohishi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Kushida</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Changes of biochemical markers during fracture
healing</article-title>. <source>Arch Orthop Traum Surg</source><year>1998</year>;
<year>118</year>: <fpage>126</fpage>&#x02013;<lpage>130</lpage>.</mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Juby</surname><given-names>AG</given-names></name><name><surname>De Geus-Wenceslau</surname><given-names>CM</given-names></name></person-group>
<article-title>Evaluation of osteoporosis treatment in seniors after hip
fracture</article-title>. <source>Osteoporos Int</source><year>2002</year>;
<year>13</year>: <fpage>205</fpage>&#x02013;<lpage>210</lpage>.<pub-id pub-id-type="pmid">11991439</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name><surname>Rabenda</surname><given-names>V</given-names></name><name><surname>Mertens</surname><given-names>R</given-names></name><name><surname>Fabri</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>Adherence to bisphosphonates therapy and hip fracture risk
in osteoporotic women</article-title>. <source>Osteoporos Int</source><year>2008</year>;
<year>19</year>: <fpage>811</fpage>&#x02013;<lpage>818</lpage>.<pub-id pub-id-type="pmid">17999022</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group><name><surname>Bell</surname><given-names>KJL</given-names></name><name><surname>Hayen</surname><given-names>A</given-names></name><name><surname>Macaskill</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Value of routine monitoring of bone mineral density after
starting bisphosphonate treatment: secondary analysis of trial data</article-title>.
<source>BMJ</source><year>2009</year>; <year>338</year>: <fpage>b2266</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.b2266</pub-id><pub-id pub-id-type="pmid">19549996</pub-id></mixed-citation></ref></ref-list></back></article>